Loading clinical trials...
Loading clinical trials...
Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation
Conditions
Interventions
CARCIK-CD19
Locations
2
Italy
Ospedale PG23
Bergamo, BG, Italy
Fondazione MBBM
Monza, MB, Italy
Start Date
December 20, 2017
Primary Completion Date
March 31, 2021
Completion Date
December 30, 2022
Last Updated
May 6, 2023
NCT05292664
NCT06316856
NCT05809284
NCT04325841
Lead Sponsor
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions